Randomized phase I trial outcomes show safe and sustainable inhibition of classical and ...

Retrieved on: 2025-08-16 13:04:18

Tags for this article:

Click the tags to see associated articles and topics

Randomized phase I trial outcomes show safe and sustainable inhibition of classical and .... View article details on hiswai:

Excerpt

Empasiprubart is a humanized recycling monoclonal antibody that inhibits both pathways by binding to the CCP2 domain of complement factor 2 (C2), an ...

Article found on: www.nature.com

View Original Article